Cargando…

Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial

IMPORTANCE: Evidence on HIV preexposure prophylaxis (PrEP) among Chinese men who have sex with men (MSM) is critical to guide its large-scale implementation in low- and middle-income countries. OBJECTIVE: To evaluate incident HIV infection, adherence, safety, and changes in sexual behaviors among MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongyi, Wang, Zixin, Huang, Xiaojie, Chen, Yaokai, Wang, Hui, Cui, Sitong, Zhang, Jing, Chu, Zhenxing, Hu, Qinghai, Ding, Haibo, Qian, Hanzhu, Zou, Huachun, Tang, Weiming, Gao, Yangyang, Jin, Xia, Liu, Zhaozhen, Zhang, Lukun, Zhao, Jin, He, Xiaoqing, Jiang, Yongjun, Geng, Wenqing, Xu, Junjie, Shang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851305/
https://www.ncbi.nlm.nih.gov/pubmed/35171258
http://dx.doi.org/10.1001/jamanetworkopen.2021.48782
_version_ 1784652794603503616
author Wang, Hongyi
Wang, Zixin
Huang, Xiaojie
Chen, Yaokai
Wang, Hui
Cui, Sitong
Zhang, Jing
Chu, Zhenxing
Hu, Qinghai
Ding, Haibo
Qian, Hanzhu
Zou, Huachun
Tang, Weiming
Gao, Yangyang
Jin, Xia
Liu, Zhaozhen
Zhang, Lukun
Zhao, Jin
He, Xiaoqing
Jiang, Yongjun
Geng, Wenqing
Xu, Junjie
Shang, Hong
author_facet Wang, Hongyi
Wang, Zixin
Huang, Xiaojie
Chen, Yaokai
Wang, Hui
Cui, Sitong
Zhang, Jing
Chu, Zhenxing
Hu, Qinghai
Ding, Haibo
Qian, Hanzhu
Zou, Huachun
Tang, Weiming
Gao, Yangyang
Jin, Xia
Liu, Zhaozhen
Zhang, Lukun
Zhao, Jin
He, Xiaoqing
Jiang, Yongjun
Geng, Wenqing
Xu, Junjie
Shang, Hong
author_sort Wang, Hongyi
collection PubMed
description IMPORTANCE: Evidence on HIV preexposure prophylaxis (PrEP) among Chinese men who have sex with men (MSM) is critical to guide its large-scale implementation in low- and middle-income countries. OBJECTIVE: To evaluate incident HIV infection, adherence, safety, and changes in sexual behaviors among MSM using daily PrEP (D-PrEP) and event-driven PrEP (ED-PrEP) in 4 cities in China. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial was conducted among HIV-seronegative MSM from December 11, 2018, to November 30, 2020, in Beijing, Shenyang, Chongqing, and Shenzhen. Participants self-chose D-PrEP or ED-PrEP regimens at baseline and could switch regimens during the 12-month study period. HIV-negative MSM who declined to initiate PrEP (nonusers) in the same cities joined a separate parallel prospective cohort and served as control individuals. INTERVENTIONS: PrEP consisted of coformulated tenofovir disoproxil fumarate, 300 mg, and emtricitabine, 200 mg. MAIN OUTCOMES AND MEASURES: The main outcome was incident HIV infection. Poisson regression was used to obtain the HIV incidence rate ratio (IRR). RESULTS: A total of 1530 MSM were included in the analysis (median age, 30 [IQR, 25-37] years). At baseline, 520 MSM chose D-PrEP (median age, 29 [IQR, 25-35] years) and 503 chose ED-PrEP (median age, 29 [IQR, 25-36] years). The median HIV Risk Index score was 18 (IQR, 12-22) among D-PrEP users and 18 (IQR, 11-22) among ED-PrEP users. Among 507 PrEP nonusers, the median age was 33 (IQR, 27-43) years, and the median HIV Risk Index score was 12 (IQR, 7-18). Although PrEP users had more baseline behaviors associated with HIV risk, the HIV incidence was lower among all PrEP users (adjusted IRR, 0.09 [95% CI, 0.04-0.21]), ED-PrEP users (adjusted IRR, 0.05 [95% CI, 0.01-0.22]), and D-PrEP users (adjusted IRR, 0.12 [95% CI, 0.04-0.33]) compared with PrEP nonusers. There was no difference in HIV incidence between D-PrEP users and ED-PrEP users (IRR, 0.33 [95% CI, 0.06-2.04]). Event-driven PrEP users consumed 40% fewer tablets than D-PrEP users during the study period. Adherence, defined as the proportion of self-reported days with sexual intercourse in which PrEP was taken according to prescription of at least 90%, increased over time among ED-PrEP users (from 57.4% to 77.8%; P < .001 for trend) and decreased over time among D-PrEP users (from 75.1% to 72.1%; P = .02 for trend). Daily PrEP users reported fewer adverse events than ED-PrEP users (193 of 520 [37.1%] vs 241 of 503 [47.9%]). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that D-PrEP and ED-PrEP regimens are associated with lower incidence of HIV and a good safety profile among high-risk MSM in China. TRIAL REGISTRATION: Chinese Clinical Trial Registry number: ChiCTR-IIN-17013762
format Online
Article
Text
id pubmed-8851305
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-88513052022-02-18 Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial Wang, Hongyi Wang, Zixin Huang, Xiaojie Chen, Yaokai Wang, Hui Cui, Sitong Zhang, Jing Chu, Zhenxing Hu, Qinghai Ding, Haibo Qian, Hanzhu Zou, Huachun Tang, Weiming Gao, Yangyang Jin, Xia Liu, Zhaozhen Zhang, Lukun Zhao, Jin He, Xiaoqing Jiang, Yongjun Geng, Wenqing Xu, Junjie Shang, Hong JAMA Netw Open Original Investigation IMPORTANCE: Evidence on HIV preexposure prophylaxis (PrEP) among Chinese men who have sex with men (MSM) is critical to guide its large-scale implementation in low- and middle-income countries. OBJECTIVE: To evaluate incident HIV infection, adherence, safety, and changes in sexual behaviors among MSM using daily PrEP (D-PrEP) and event-driven PrEP (ED-PrEP) in 4 cities in China. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial was conducted among HIV-seronegative MSM from December 11, 2018, to November 30, 2020, in Beijing, Shenyang, Chongqing, and Shenzhen. Participants self-chose D-PrEP or ED-PrEP regimens at baseline and could switch regimens during the 12-month study period. HIV-negative MSM who declined to initiate PrEP (nonusers) in the same cities joined a separate parallel prospective cohort and served as control individuals. INTERVENTIONS: PrEP consisted of coformulated tenofovir disoproxil fumarate, 300 mg, and emtricitabine, 200 mg. MAIN OUTCOMES AND MEASURES: The main outcome was incident HIV infection. Poisson regression was used to obtain the HIV incidence rate ratio (IRR). RESULTS: A total of 1530 MSM were included in the analysis (median age, 30 [IQR, 25-37] years). At baseline, 520 MSM chose D-PrEP (median age, 29 [IQR, 25-35] years) and 503 chose ED-PrEP (median age, 29 [IQR, 25-36] years). The median HIV Risk Index score was 18 (IQR, 12-22) among D-PrEP users and 18 (IQR, 11-22) among ED-PrEP users. Among 507 PrEP nonusers, the median age was 33 (IQR, 27-43) years, and the median HIV Risk Index score was 12 (IQR, 7-18). Although PrEP users had more baseline behaviors associated with HIV risk, the HIV incidence was lower among all PrEP users (adjusted IRR, 0.09 [95% CI, 0.04-0.21]), ED-PrEP users (adjusted IRR, 0.05 [95% CI, 0.01-0.22]), and D-PrEP users (adjusted IRR, 0.12 [95% CI, 0.04-0.33]) compared with PrEP nonusers. There was no difference in HIV incidence between D-PrEP users and ED-PrEP users (IRR, 0.33 [95% CI, 0.06-2.04]). Event-driven PrEP users consumed 40% fewer tablets than D-PrEP users during the study period. Adherence, defined as the proportion of self-reported days with sexual intercourse in which PrEP was taken according to prescription of at least 90%, increased over time among ED-PrEP users (from 57.4% to 77.8%; P < .001 for trend) and decreased over time among D-PrEP users (from 75.1% to 72.1%; P = .02 for trend). Daily PrEP users reported fewer adverse events than ED-PrEP users (193 of 520 [37.1%] vs 241 of 503 [47.9%]). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that D-PrEP and ED-PrEP regimens are associated with lower incidence of HIV and a good safety profile among high-risk MSM in China. TRIAL REGISTRATION: Chinese Clinical Trial Registry number: ChiCTR-IIN-17013762 American Medical Association 2022-02-16 /pmc/articles/PMC8851305/ /pubmed/35171258 http://dx.doi.org/10.1001/jamanetworkopen.2021.48782 Text en Copyright 2022 Wang H et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Wang, Hongyi
Wang, Zixin
Huang, Xiaojie
Chen, Yaokai
Wang, Hui
Cui, Sitong
Zhang, Jing
Chu, Zhenxing
Hu, Qinghai
Ding, Haibo
Qian, Hanzhu
Zou, Huachun
Tang, Weiming
Gao, Yangyang
Jin, Xia
Liu, Zhaozhen
Zhang, Lukun
Zhao, Jin
He, Xiaoqing
Jiang, Yongjun
Geng, Wenqing
Xu, Junjie
Shang, Hong
Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title_full Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title_fullStr Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title_full_unstemmed Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title_short Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China: A Nonrandomized Controlled Trial
title_sort association of hiv preexposure prophylaxis use with hiv incidence among men who have sex with men in china: a nonrandomized controlled trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851305/
https://www.ncbi.nlm.nih.gov/pubmed/35171258
http://dx.doi.org/10.1001/jamanetworkopen.2021.48782
work_keys_str_mv AT wanghongyi associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT wangzixin associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT huangxiaojie associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT chenyaokai associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT wanghui associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT cuisitong associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT zhangjing associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT chuzhenxing associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT huqinghai associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT dinghaibo associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT qianhanzhu associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT zouhuachun associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT tangweiming associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT gaoyangyang associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT jinxia associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT liuzhaozhen associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT zhanglukun associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT zhaojin associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT hexiaoqing associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT jiangyongjun associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT gengwenqing associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT xujunjie associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial
AT shanghong associationofhivpreexposureprophylaxisusewithhivincidenceamongmenwhohavesexwithmeninchinaanonrandomizedcontrolledtrial